Fig. 6: Circulating tumor DNA (ctDNA) and gene set enrichment analysis. | Nature Communications

Fig. 6: Circulating tumor DNA (ctDNA) and gene set enrichment analysis.

From: Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights

Fig. 6

a Bar plot showing the percentage of patients with ctDNA detected before surgery, stratified across different risk groups. b Bar plot showing the percentage of patients with ctDNA clearance status (Persistent, Cleared, Never Detected) after SOC therapy, stratified across different risk groups. c C-index comparison of three different RFS prediction models using combinations of clinical features, tumor volume, imaging subtypes, and serial ctDNA (ctDNA detection at pre-surgery and ctDNA clearance status after SOC therapy). d Top 10 Hallmark Pathways differentially active in high- versus low-risk group according to the meta-analysis of the studied cohorts. Source data are provided as a Source Data file.

Back to article page